Detalhe da pesquisa
1.
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Cancer Immunol Immunother
; 73(7): 116, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713408
2.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Future Oncol
; 20(15): 959-968, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390818
3.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961119
4.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med
; 29(11): 2835-2843, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845511
5.
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
J Clin Oncol
; 41(23): 3917-3929, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307514
6.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Clin Cancer Res
; 29(17): 3352-3361, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058595
7.
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Eur J Cancer
; 173: 285-296, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964471
8.
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
Melanoma Res
; 31(1): 67-75, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33234846
9.
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
J Immunother Cancer
; 9(8)2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452930
10.
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med
; 30(2): 607, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923838
11.
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med
; 30(3): 906, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177857